Mediwelcome Healthcare Management & Technology (HKSE:02159) Research & Development: HK$30.8 Mil (TTM As of Dec. 2025)


HKSE:02159 Mediwelcome Healthcare Management & Technology Inc HKSE:02159
54 GF Score
Price HK$1.61
GF Value HK$0.69
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mediwelcome Healthcare Management & Technology Research & Development?

Mediwelcome Healthcare Management & Technology HKSE:02159 -0.62% 54 Research & Development is HK$30.8 Mil as of Dec. 2025. GuruFocus rates HKSE:02159 with a GF Score™ of 54/100 and a GF Value™ of HK$0.69 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Mediwelcome Healthcare Management & Technology's Research & Development for the six months ended in Dec. 2025 was HK$23.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$30.8 Mil.

Mediwelcome Healthcare Management & Technology  (HKSE:02159) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Mediwelcome Healthcare Management & Technology Research & Development Related Terms

Mediwelcome Healthcare Management & Technology Research & Development Historical Data

* Premium members only.

The historical data trend for Mediwelcome Healthcare Management & Technology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mediwelcome Healthcare Management & Technology Research & Development Chart

Mediwelcome Healthcare Management & Technology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 22.89 56.52 35.75 19.94 30.86

Mediwelcome Healthcare Management & Technology Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.32 12.97 7.08 6.89 23.90
HKSE:02159
54GF Score
Mediwelcome Healthcare Management & Technology Inc HKSE:02159
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mediwelcome Healthcare Management & Technology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$30.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$30.8 Mil mean?
Mediwelcome Healthcare Management & Technology (HKSE:02159) has a Research & Development of HK$30.8 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Mediwelcome Healthcare Management & Technology and its competitors.
Is Mediwelcome Healthcare Management & Technology's Research & Development too high?
Mediwelcome Healthcare Management & Technology's current Research & Development is HK$30.8 Mil. Overall, Mediwelcome Healthcare Management & Technology has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mediwelcome Healthcare Management & Technology's Research & Development compare to VEEV and BTSG?
Mediwelcome Healthcare Management & Technology's Research & Development of HK$30.8 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Mediwelcome Healthcare Management & Technology and its competitors. Mediwelcome Healthcare Management & Technology's current Research & Development is HK$30.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mediwelcome Healthcare Management & Technology stock overvalued right now?
Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology (HKSE:02159) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.69, compared to a current price of HK$1.61 — trading 133.3% above its estimated fair value. The current Research & Development is HK$30.8 Mil. Mediwelcome Healthcare Management & Technology's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Mediwelcome Healthcare Management & Technology (HKSE:02159), the current Research & Development is HK$30.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mediwelcome Healthcare Management & Technology (HKSE:02159) Overvalued in 2026?

Based on GuruFocus' analysis, Mediwelcome Healthcare Management & Technology stock appears to be overvalued. The current stock price of HK$1.61 is trading 133.3% above its estimated GF Value™ of HK$0.69. GuruFocus considers Mediwelcome Healthcare Management & Technology to be Significantly Overvalued.

Key valuation signals for HKSE:02159:

  • Research & Development: HK$30.8 Mil
  • GF Value™: HK$0.69 vs. price of HK$1.61 (133.3% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02159 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mediwelcome Healthcare Management & Technology Business Description

Address Wangjingdongyuan Zone 4, Wangjing East Park, 17th Floor, Block B, Greenland Center, Chaoyang District, Beijing, CHN, 100101
Mediwelcome Healthcare Management & Technology Inc is an investment holding company. The Group mainly provides medical conference services, patient education and screening services, and marketing and consulting services, in addition to providing integrated healthcare marketing solutions. Its products and services include Academic Conference Management System, Scientific Research Data Reporting System, the Health/Medical Media Matrix, patient management services, and marketing and consulting services. The Group has only one reportable segment, mainly operating its businesses in the PRC and earning revenue from the PRC.
54GF Score

Get the complete analysis for HKSE:02159

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.61
Price
HK$0.69
GF Value